01
ACTIPONIN®

Botanical origin.
Defined by science.

Actiponin® is a standardized Gynostemma pentaphyllum extract developed through patented technology and characterized by its signature compounds, Damulin A and Damulin B.

GYNOSTEMMABOTANICAL ORIGIN
4-COUNTRYPATENTS
DAMULIN A/BSIGNATURE COMPOUNDS
HUMANCLINICAL EVIDENCE
02 · BOTANICAL ORIGIN

Gynostemma pentaphyllum.

The botanical foundation of Actiponin®.

Gynostemma pentaphyllum, also known as Jiaogulan or Dolwoe, is a climbing botanical found across East Asia.

Its leaves are naturally rich in saponins and provide the botanical starting point for the standardized Actiponin® ingredient.

BOTANICAL NAMEGynostemma pentaphyllum
PART USEDLeaf
ORIGINEast Asia
BOTANICAL CHARACTERSaponin-rich climbing vine
Gynostemma pentaphyllum leaves
Gynostemma cultivation landscape
Gynostemma leaf detail
03 · PATENT PROCESSING

Patented technology. Defined consistency.

Our proprietary, patented process is designed to deliver a consistent Actiponin® ingredient from selected Gynostemma leaves through controlled processing and standardization.

Selected Leaves Carefully selected
Gynostemma pentaphyllum leaves
Patented Processing Proprietary processing designed
to preserve key ingredient characteristics
Standardization Standardized to a defined
Damulin A & B profile
Actiponin® Standardized botanical extract
ready for formulation
PATENTED IN
FOUR MAJOR MARKETS
Korea flagKorea
United States flagUnited States
Japan flagJapan
China flagChina
04
SIGNATURE COMPOUNDS

Defined by Damulin A & Damulin B.

Damulin A and Damulin B are dammarane-type saponins used to characterize the chemical identity of Actiponin®.

EXPLORE RESEARCH
Damulin A structureDAMULIN A
Damulin B structureDAMULIN B
05 · ACTIPONIN® & AMPK

Actiponin®
& AMPK

Exploring the relationship between Actiponin® and AMPK-related signaling.

Research on Actiponin® and its signature compounds, Damulin A and Damulin B, has investigated their relationship with AMPK-related signaling.

EXPLORE THE RESEARCH
ACTIPONIN®Standardized botanical extract
Damulin ASignature compound
Damulin BSignature compound
AMPK RELATED SIGNALING
An illustrative research framework
05A · BODY FAT

AMPK signaling
and body fat
metabolism.

Actiponin® research has investigated AMPK-related pathways associated with lipid metabolism and body fat regulation.

SEE BODY-FAT CLINICAL EVIDENCE
01
AMPK SIGNALING

AMPK-related signaling is explored as a cellular energy-sensing pathway.

02
FAT OXIDATION ↑
Illustrative 3D cutaway of a mitochondrion with its folded inner membrane

Activated AMPK is associated with pathways involved in fatty-acid oxidation.

03
FAT ACCUMULATION ↓
Illustrative 3D adipocyte cutaway with a large lipid droplet and peripheral nucleus

These pathways are studied in relation to body-fat regulation.

AMPK, AMP-activated protein kinase.
05B · JOINT HEALTH

AMPK signaling
in joint health.

Actiponin® research has investigated AMPK-related signaling in pathways associated with joint tissue homeostasis and cartilage health.

SEE JOINT CLINICAL EVIDENCE
01
AMPK SIGNALING

AMPK-related signaling

02
CARTILAGE HOMEOSTASIS
Illustrative 3D cartilage matrix with dispersed chondrocytes

Pathways associated with cartilage cell homeostasis

03
JOINT HEALTH
Illustrative 3D knee joint with pearl-colored bone and teal cartilage

Research related to joint comfort and function

06 · THREE HEALTH TERRITORIES

Three benefits.
One biology.

Actiponin® brings together three clinically documented health territories: body-fat management, cholesterol support, and joint health.

ACTIPONIN® AMPK-ON™ Platform
01
METABOLIC

Body Fat Reduction

Human research focused on body-fat mass and abdominal-fat outcomes.

−1.25 kg body fat mass
02
CARDIOVASCULAR

Cholesterol Reduction

Clinical research evaluated changes in total and LDL cholesterol.

−9.69 mg/dL total cholesterol
03
JOINT & MOBILITY

Joint Health

Human research focused on joint comfort, mobility and functional outcomes.

WOMAC / VAS clinical outcomes
07 · HUMAN CLINICAL EVIDENCE

Three benefits.
Clinically documented.

Actiponin® has been evaluated in 12-week randomized, double-blind, placebo-controlled human studies across body-fat, cholesterol, and joint-health endpoints.

Study counts and summary figures follow the supplied company brochure. Publication and full-report availability differ by study; see the source notes below.

3Human Studies
290Participants
12Weeks Each
01 METABOLIC

Body Fat Reduction

−1.25 kg

Body fat mass · n = 80

02 CARDIOVASCULAR

Cholesterol Reduction

−9.69 mg/dL

Total cholesterol · n = 60

03 JOINT & MOBILITY

Joint Health

−8.7

WOMAC total change · n = 150

Randomized · Double-blind · Placebo-controlled · 12 weeks
07A · METABOLIC HEALTH

Body Fat
Reduction.

12 weeks n = 80 450 mg/day

Actiponin® was evaluated over 12 weeks for changes in body composition and abdominal fat in a randomized, double-blind, placebo-controlled human study.

Study safety summary No clinically significant safety changes were reported in the published study.
KEY CLINICAL OUTCOMES
BODY FAT MASS −1.25 kg Change from baseline
TOTAL ABDOMINAL FAT AREA −20.9 cm² Change from baseline
Park SH, et al. (2014). Obesity. 22(1):63–71. doi:10.1002/oby.20539. Displayed baseline-change figures are cited from the supplied 2026 company brochure. Full study tables are available on request.
07B · CARDIOVASCULAR HEALTH

Cholesterol
Reduction.

12 weeks Company brochure summary

Actiponin® was evaluated over 12 weeks for changes in blood cholesterol in a randomized, double-blind, placebo-controlled human study.

Clinically documented outcomes Reductions in total cholesterol and LDL cholesterol were reported in the study materials.
KEY CLINICAL OUTCOMES
TOTAL CHOLESTEROL −9.69 mg/dL 12-week change
LDL CHOLESTEROL −11.1 mg/dL 12-week change
TOTAL CHOLESTEROL
−9.69 mg/dL
LDL CHOLESTEROL
−11.1 mg/dL
12-WEEK RANDOMIZED · DOUBLE-BLIND · PLACEBO-CONTROLLED HUMAN STUDY · n = 60
01 · TOTAL CHOLESTEROL−9.69 mg/dL
02 · LDL CHOLESTEROL−11.1 mg/dL
AMPK-related metabolic context AMPK signaling is studied in lipid metabolism, including pathways involved in fatty-acid oxidation and selected lipid/cholesterol biosynthetic processes.
Actiponin® Trade Show Brochure 2026 · Cardiovascular clinical summary. The brochure cites n = 60. A separate supplied cholesterol summary reports different change values; the original clinical report is required to reconcile them. These figures are not independently verified.
07C · JOINT HEALTH

Joint Comfort
& Mobility.

12 weeks n = 150 450 / 900 mg/day

Actiponin® was evaluated over 12 weeks for changes in joint-related symptoms and functional outcomes in a randomized, double-blind, placebo-controlled human study.

Company study safety summary No serious adverse events were reported in the supplied summary. This is not a general safety guarantee.
KEY CLINICAL OUTCOMES

WOMAC

Total-score change at Week 12

Placebon = 50
−1.6 ± 0.4
450 mg/dayn = 50
−8.7 ± 0.4
900 mg/dayn = 50
−10.1 ± 0.4

LSMean ± SE · p < 0.0001 vs. placebo for both doses

Knee-pain VAS

Change at Week 12 · millimeters

Placebon = 50
−3.1 ± 0.8
450 mg/dayn = 50
−13.1 ± 0.7
900 mg/dayn = 50
−18.4 ± 0.7

LSMean ± SE · p < 0.0001 vs. placebo for both doses

Source: supplied TG Biotech Buyer Proposal, July 2026, p. 4 · protocol NC04-TGB-2025. Company-reported summary, not an independent review of the full clinical dataset. Detailed clinical documents are available on request.
08 · REGULATORY & CERTIFICATION

Verified beyond
the laboratory.

Actiponin® is supported by regulatory recognition, third-party certifications and technical documentation for global partner evaluation.

UNITED STATESFDA NDI NotificationNo. 1284
KOREAMFDS Functional IngredientBody-Fat Reduction

The supplied FDA correspondence is dated May 12, 2023; NDI No. 1284 is cited in company materials. An NDI notification is not FDA approval of a finished product. Conditions of use, certification scope and permitted claims must be checked for each market.

HALALCertified VEGANCertified SAFETYDocumentation ANALYSISCertificate GMPManufacturing
09 · INTELLECTUAL PROPERTY

Protected across
key global
markets.

Actiponin® is supported by patent and trademark protection across major global markets.

PATENT MARKETS
PATENTED PROCESSFour global markets.Protected technology. Defined consistency.
Korea flagKorea
United States flagUnited States
Japan flagJapan
China flagChina
01 · PATENT PORTFOLIO

Patented in four
major markets

Korea · United States · Japan · China

VIEW PATENT PORTFOLIO
02 · TRADEMARK PROTECTION

Actiponin® trademark
protection across key markets

Korea · U.S. · Europe · U.K. · Japan · China · Australia

VIEW TRADEMARK PORTFOLIO

Our intellectual property portfolio underpins the global value and sustainable growth of Actiponin®.

10 · INDUSTRY RECOGNITION

Recognized by
the industry.

Life Extension AMPK Metabolic Activator, formulated with Actiponin®, was recognized in the Weight Loss category of the 2020 Natural Choice Awards by WholeFoods Magazine.

VIEW AWARD FEATURE
INDUSTRY RECOGNITION · 2020Natural Choice AwardsWeight Loss Category
WholeFoods Magazine — original publisher logo from the supplied award feature
Life Extension AMPK Metabolic Activator — original product photograph from the supplied award feature
RECOGNIZED PRODUCT

Life Extension
AMPK Metabolic Activator

Formulated with Actiponin®

View original award feature
11 · EVIDENCE LIBRARY

Explore all evidence.
Backed by science.

Access the scientific, clinical, regulatory and technical documentation behind Actiponin®.

01

Scientific Publications

Peer-reviewed research and scientific publications.
02

Clinical Studies

Human clinical evidence across metabolic, cardiovascular, and joint health.
03

Patents

Patent portfolio and protected processing technologies.
04

Regulatory Documents

Regulatory recognition and compliance documentation.
05

Certifications & Quality

Certifications, quality standards and assurance systems.
06

Technical Documentation

Ingredient specifications, summaries and partner resources.
Looking for a specific document?Contact us and our team will assist you.
CONTACT US